Short answer
NeuroPace Inc (NPCE) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $22M (down 2.0% year over year) with net income of −$7M.
Q1 2026 key financials · XBRL
- Revenue
- $22M
- −2.0% YoY
- Net income
- −$7M
- −1.5% YoY
- Operating margin
- -25.2%
- Gross margin
- 81.8%
- EPS (diluted)
- −$0.20
- +4.8% YoY
Source: XBRL data from the NeuroPace Inc (NPCE) Q1 2026 10-Q on SEC EDGAR. USD.
NeuroPace Inc Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $22.1M, down 2% YoY from $22.5M, primarily reflecting DIXI distribution termination
- Gross margin 81.8% vs 77.0% YoY, driven by discontinued lower-margin DIXI products
- RNS System units increased with higher initial implants and replacements; DIXI revenue ended
- Cash, equivalents and short-term investments $54.0M; outstanding debt $59.0M
- Continued net losses and negative cash flows expected near term; potential additional funding may be required
Risk Factors
- Newly triggered manufacturing-compliance risk: QMSR superseded QSR on February 2, 2026, increasing quality-system requirements
- Regulatory risk: FDA staffing changes could delay indication-expansion reviews for generalized epilepsy and ages 12–17
- Operational risk: Single-source suppliers provide key batteries and printed circuit assemblies, with alternatives requiring several months to qualify
- Commercial risk: RNS System remains limited to adults with drug-resistant focal epilepsy in the United States
- Financial risk: Term Loan Agreement includes restrictive and financial maintenance covenants, with default potentially accelerating repayment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NeuroPace Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.